A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD

BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting β(2)-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (...

Descripción completa

Detalles Bibliográficos
Autores principales: Siler, Thomas M, Donald, Alison C, O’Dell, Dianne, Church, Alison, Fahy, William A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869636/
https://www.ncbi.nlm.nih.gov/pubmed/27274218
http://dx.doi.org/10.2147/COPD.S102962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869636/
https://www.ncbi.nlm.nih.gov/pubmed/27274218
http://dx.doi.org/10.2147/COPD.S102962

Ejemplares similares